What is Entrada Therapeutics's market cap?

Entrada Therapeutics (TRDA) has a market capitalization of $236.0M and trades on NASDAQ.

Who are Entrada Therapeutics's competitors?

Entrada Therapeutics's key competitors include Sarepta Therapeutics, PTC Therapeutics, Edgewise Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Entrada Therapeutics partner with?

Entrada Therapeutics's notable partners include Vertex Pharmaceuticals Incorporated.

Where is Entrada Therapeutics headquartered?

Entrada Therapeutics is headquartered in United States of America and employs approximately 159 people. It has been publicly traded since 2021.

Entrada Therapeutics

TRDA

Entrada Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines designed to engage previously inaccessible intracellular targets.

Market cap

$236.03M-6.3%

Table of contents

Earnings

Q1 2026 report

May 7, 2026

Revenue$875.0KMiss by $2.0M EPS-$0.95Beat by $0.11

Read the full report

Next report

Aug 5, 2026 (In 1 week)

Revenue estimate$2.2M

EPS estimate-$1.05

Competitors

By market cap

PTC Therapeutics$6.3B+78.9%

Scholar Rock$5.9B+66.5%

Edgewise Therapeutics, Inc.$4.5B+198%

Dyne Therapeutics, Inc.$4.2B+222%

Sarepta Therapeutics, Inc.$1.7B+23.2%

Prime Medicine$543.7M-1.2%

Entrada Therapeutics$236.0M-0.2%

PepGen$131.4M+181%

By revenue growth

Scholar Rock+76.4%

Sarepta Therapeutics, Inc.+9.9%

PTC Therapeutics-53.3%

By net margin

PTC Therapeutics42.25%+119pp

Sarepta Therapeutics, Inc.4.64%-38.4pp

Scholar Rock-236.95%+173pp

Prime Medicine-4,342.44%—

Profile

Entrada Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines designed to engage previously inaccessible intracellular targets. The company utilizes its proprietary Endosomal Escape Vehicle (EEV) platform to deliver therapeutic conjugates, such as oligonucleotides and proteins, into cells to treat genetic neuromuscular and inherited retinal diseases. Its core value proposition lies in significantly improving the efficiency of endosomal escape, allowing for higher therapeutic activity at lower doses compared to traditional biologics.

Competitive position

Entrada is a pioneer in endosomal escape technology, positioning its EEV-PMO candidates as potential best-in-class therapies with superior intracellular delivery compared to existing PMO-based treatments.

GeographiesUnited States, United Kingdom, European Union

Customer segmentsPediatric patients, Adult patients with rare genetic disorders

Business modelR&D intensive, Licensing and Partnerships

SuppliersOligonucleotide manufacturers, Peptide synthesis providers, Clinical research organizations (CROs)

CustomersSpecialty pharmacies, Hospitals, Academic medical centers

CountryUnited States of America

Listed2021

Employees159.0

CEODipal Doshi

SectorHealthcare

IndustryBiotechnology

Websiteentradatx.com

FilingsSEC EDGAR

Questions, answered.

What is Entrada Therapeutics's market cap?: Entrada Therapeutics (TRDA) has a market capitalization of $236.0M and trades on NASDAQ.
Who are Entrada Therapeutics's competitors?: Entrada Therapeutics's key competitors include Sarepta Therapeutics, PTC Therapeutics, Edgewise Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Entrada Therapeutics partner with?: Entrada Therapeutics's notable partners include Vertex Pharmaceuticals Incorporated.
Where is Entrada Therapeutics headquartered?: Entrada Therapeutics is headquartered in United States of America and employs approximately 159 people. It has been publicly traded since 2021.